AstraZeneca Reports Results of Roxadustat in Global Phase III Programme for Cardiovascular Safety in Patients with Chronic Kidney Disease


  • The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9,000+ patients with anemia + CKD not on dialysis (NDD) , dialysis-dependent (DD), ID respectively
  • Pooled analyses results: MACE/MACE+ in NDD & DD patients, clinically no difference; MACE/MACE+ in ID patients shows better results
  • Roxadustat is hypoxia-inducible-factor prolyl hydroxylase inhibitor, evaluated under the collaboration of AstraZeneca, FibroGen and Astellas with its expected FDA’s regulatory submission in H2’19

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter